Sanofi SA SNY announced the withdrawal of its regulatory application in Europe for Dupixent (dupilumab) to treat adults with ...
Nemolizumab may be more effective across key pruritus and disease severity measures than dupilumab for patients with PN.
Treatment with dupilumab for 52 weeks is associated with improvement in height and BALP levels among pediatric patients with severe AD.
Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.
Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP ...
The Society for Advanced Bronchoscopy (SAB) and National Association of Veterans Research Education Foundations (NAVREF) hosted webinars featuring multi-disciplinary panels of physicians who discussed ...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July ...
A revolutionary injection for chronic obstructive pulmonary disorder (COPD) is being rolled out on the NHS. The jab tackles the inflammation driving symptoms and could benefit up to 30,000 people with ...
CINCINNATI, June 29, 2026 /PRNewswire/ -- When people have the rare disease eosinophilic gastritis (EoG), many common foods can trigger severe stomach reactions – including dairy, wheat, gluten, egg, ...
In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis, ...
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results